DT-216P2
Phase 2Small molecule
DT-216P2 is one of 12 small molecule programs targeting Single Ascending Dose. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Single Ascending Dose
#DrugCompanyPhaseTrials
1DT-216P2
DDesign Therapeutics, Inc.
Phase 2
WVE-006
WWave Life Sciences Ltd.
Phase 2
JMT202
SShanghai JMT-Bio Inc.
Phase 1
HRS-4029
BBeijing Suncadia Pharmaceuticals Co., Ltd
Phase 1
Gensci142
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 1
SYH2085
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 1
NM-101
NNeuramedy Co. Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DT-216P2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDesign Therapeutics, Inc.